CUE Biopharma CEO Dan Passeri, J.D. joins us for a discussion on the development of the company’s Immuno-STAT platform for the selective targeting and alteration of T cells. Passeri shares the rationale behind his belief in the company’s immunotherapeutic approach, and how the CUE-100 series of candidates in its pipeline are being developed to address a scourge of HPV-related head, neck, and other cancers.